Aberrant expression of c-Myc has been described in various hematologic malignancies, including Burkitt lymphoma, “double-hit/ “triple-hit” DLBCLs, high-grade B-cell lymphomas, multiple myeloma (MM), some mantle cell lymphomas, and AMLs. Here, MYC is linked to Burkitt lymphoma.